NDC 0591-3660 – Desvenlafaxine
Desvenlafaxine Succinate 100 mg/1 · Tablet, Extended Release · Oral
Product NDC0591-3660
Product details
- Brand name
- Desvenlafaxine
- Generic name
- Desvenlafaxine
- Labeler
- Actavis Pharma, Inc.
- Dosage form
- Tablet, Extended Release
- Route
- Oral
- Marketing category
- ANDA · ANDA204065
- Marketed since
- March 1, 2017
- Marketing end
- January 31, 2027
- Pharmacologic class
- Serotonin and Norepinephrine Reuptake Inhibitor
Active ingredients
- Desvenlafaxine Succinate 100 mg/1
Uses, dosage, side effects and warnings for Desvenlafaxine →
Package NDC codes (1)
| Package NDC | Description | Since |
|---|---|---|
| 0591-3660-30 | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0591-3660-30) | Mar 1, 2017 |
Recalls mentioning this NDC
- D-0581-2021 Jun 2, 2021 · Class II
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Other Desvenlafaxine products
- 50090-5293 Desvenlafaxine Succinate 50 mg/1 · Tablet, Extended Release · A-S Medication Solutions
- 50090-6738 Desvenlafaxine Succinate 25 mg/1 · Tablet, Extended Release · A-S Medication Solutions
- 50090-5274 Desvenlafaxine Succinate 25 mg/1 · Tablet, Extended Release · A-S Medication Solutions
- 50090-7737 Desvenlafaxine Succinate 50 mg/1 · Tablet, Extended Release · A-S Medication Solutions
- 50090-7190 Desvenlafaxine Succinate 25 mg/1 · Tablet, Extended Release · A-S Medication Solutions
- 0591-3659 Desvenlafaxine Succinate 50 mg/1 · Tablet, Extended Release · Actavis Pharma, Inc.
- 0591-4060 Desvenlafaxine Succinate 25 mg/1 · Tablet, Extended Release · Actavis Pharma, Inc.
- 72888-143 Desvenlafaxine Succinate 50 mg/1 · Tablet, Extended Release · Advagen Pharma Ltd
- 72888-175 Desvenlafaxine Succinate 25 mg/1 · Tablet, Extended Release · Advagen Pharma Ltd
- 72888-144 Desvenlafaxine Succinate 100 mg/1 · Tablet, Extended Release · Advagen Pharma Ltd
- 46708-540 Desvenlafaxine Succinate 50 mg/1 · Tablet, Extended Release · Alembic Pharmaceuticals Limited
- 46708-541 Desvenlafaxine Succinate 100 mg/1 · Tablet, Extended Release · Alembic Pharmaceuticals Limited